Bella 1 Capsule (Bupropion HCl / Phentermine HCl / Topiramate / Naltrexone HCl / Methylcobalamin) (Slow Release) (Each)
Bella 2 Capsule (Bupropion HCl / Phentermine HCl / Topiramate / Naltrexone HCl / Methylcobalamin) (Slow Release) (Each)
Bella 3 Capsule (Bupropion HCl / Caffeine / Oxytocin / Topiramate / Naltrexone HCl / Methylcobalamin) (Each)
Bella 4 Capsule (Bupropion HCl / Phentermine HCl / Topiramate / Naltrexone HCl / Methylcobalamin) (Slow Release) (Each)
Bella 5 Capsule (Bupropion HCl / Naltrexone HCl / Topiramate)(Each)
Bella Decaf Capsule (Bupropion HCl / Oxytocin / Topiramate / Naltrexone HCl / Methylcobalamin) (Each)
Bella Plus Capsule (Bupropion HCl / Caffeine / Metformin / Oxytocin / Topiramate / Naltrexone HCl / Methylcobalamin) (Each)
Bella Plus Decaf Capsule (Bupropion HCl / Metformin / Oxytocin / Topiramate / Naltrexone HCl / Methylcobalamin) (Each)

is essential for nerve health and blood formation. While rare, deficiencies can lead to anemia and nerve damage, especially in older adults or strict vegetarians. It’s usually found in animal-based foods like meat and dairy.

It boosts alertness and energy and is often used to treat headaches or tiredness.

It also influences bonding behaviors between mothers and children and has been studied for social impairments in autism.

It helps regulate blood sugar levels and supports fertility by lowering excess androgens. It’s considered safe and effective, even when combined with lifestyle changes.

Each of these medications plays a unique role in improving health, but they also come with risks. Side effects, potential drug interactions, and individual health conditions must be carefully considered before starting treatment. Doctors typically evaluate each patient’s specific needs, weighing the benefits of treatment against possible complications.

Staying informed and working closely with healthcare providers ensures that these medications are used safely and effectively. Whether managing mental health, addiction, or chronic illnesses, understanding how these drugs work empowers people to take control of their health journey.

These medications work in different ways to help with health conditions like depression, obesity, seizures, addiction, diabetes, and more. Even though their effects can be complex, understanding how they work helps patients feel more confident in their treatment.

These chemicals are important for mood and motivation. By doing this, bupropion can reduce cravings for nicotine and ease withdrawal symptoms. However, it doesn’t affect serotonin like many other antidepressants do, and its full effects on depression may take a few weeks to appear.

Phentermine helps with short-term weight loss by stimulating the release of norepinephrine and dopamine, which can reduce appetite. It acts on the brain’s satiety center, helping people feel full sooner. But it’s not meant for long-term use because the body quickly develops tolerance, meaning higher doses are needed for the same effect.

It works by calming overactive nerve signals and enhancing the action of GABA, a calming neurotransmitter. It also blocks certain glutamate receptors that excite the brain, which helps control abnormal nerve activity. Beyond seizure control, it may also protect the brain from damage caused by oxygen deprivation.

It helps reduce cravings and the rewarding “high” associated with drug or alcohol use. Importantly, it doesn’t block other substances like alcohol or cocaine in the same way, and it doesn’t cause withdrawal itself.

Methylcobalamin (Vitamin B12) plays a key role in producing energy, making red blood cells, and maintaining nerve health. It’s essential for converting certain amino acids into important molecules like methionine and succinyl-CoA, which are needed for DNA production and energy metabolism. A deficiency can lead to anemia and nerve damage.

It blocks adenosine, a chemical that slows down nerve activity, making you feel more awake and alert. It also improves blood flow and can help treat breathing problems in premature infants.

Oxytocin is known as the “love hormone.” It helps with childbirth by stimulating uterine contractions and assists breastfeeding by promoting milk release. It’s also linked to social bonding and trust, although much about its broader effects is still being studied.

Metformin helps lower blood sugar in people with type 2 diabetes by improving how the body uses insulin. It reduces sugar production in the liver, limits absorption from the intestines, and helps muscles absorb sugar more efficiently. It also supports weight management and can help treat conditions like PCOS by balancing hormones and improving fertility.

Together, these medications represent how science harnesses the body’s natural processes to treat a wide range of health challenges, offering hope and better quality of life.

This treatment may be dangerous in light of a number of pre-existing illnesses.

Conditions influencing the central nervous system could also rule against using Bella. The presence of a seizure illness is a severe contraindication mostly because bupropion lowers the seizure threshold.

Bella is clearly contraindicated in people addicted to opioids or taking opioid analgesics as it contains naltrexone; it would trigger an acute opioid Withdrawal impairs opioid pain reduction as well. Bella must be stopped well in advance—usually 7–10 days prior—should a patient need opioid treatment (e.g., following an injury or to support surgery) to enable opioids to be effective.

Because Bella Capsules contain several components, a thorough check of concomitant medications is vital to prevent unfavorable interactions. A rigid nogo: combining any Bella component with an MAOI can induce a hypertensive crisis (dangerously high blood pressure).

With other stimulants, Bella’s stimulant agents—phentermine and caffeine—have additive effects; hence, coadministration with other weightloss medicines, amphetamines or ADHD drugs, or even high Doses of decongestants like pseudoephedrine can considerably increase heart rate and blood pressure. Patients should also restrict other caffeine sources (energy drinks, etc.) to prevent heart palpitations or jitteriness.

Alternatively, phentermine could counteract sedative drugs; for instance, it could diminish the efficacy of betablockers or other blood pressure treatments. counters the bloodpressure-reducing effect of such drugs.) Since weight reduction and appetite suppression help diabetic patients on insulin or sulfonylureas might have hypoglycemia while consuming Bella; blood glucose should Be watched and diabetic drugs changed as necessary.

The bupropion ingredient of Bella has substantial medication interactions by means of metabolic routes. A powerful inhibitor of the liver enzyme CYP2D6, bupropion may increase levels of other medications metabolized by CYP2D6. Certain antidepressants (SSRIs and tricyclics), antipsychotics, betablockers, and Type 1C antiarrhythmic medicines are among those included. Doctors might have to use lower dosages of the afflicted medicine and watch for increased effects if Bella has to be taken with such drugs (or Side effects from greater exposure

Extreme care or not at all should be used for bupropion and other medications that lower seizure threshold; for instance, concurrent usage of systemic Further lowering of seizure risk are corticosteroids, other antidepressants or stimulants, tramadol, or theophylline. Taking Bella with alcohol also calls for prudence: although limited consumption of alcohol may be acceptable, excessive drinking or sudden withdrawal—especially in a person who was a bupropion can cause seizures or neuropsychiatric symptoms in heavy drinkers.

Bella Capsules can cause a number of adverse effects, comparable to those associated with each of its component medications. Common symptoms are gastrointestinal: many patients have constipation, dry mouth, or nausea (sometimes severe with the naltrexone element). For instance, roughly a third of patients in clinical studies of the bupropion/naltrexone combination reported nausea.

Some of Bella’s customers also have headaches or lightheadedness; others have dizziness or tingling in the fingers and toes (paresthesia). Another often seen adverse effect, reflecting the stimulant qualities of phentermine and bupropion, is insomnia or sleep issues. Conversely, a few people may experience lethargy or drowsiness (topiramate and oxytocin can have sedative effects in some).

Other often experienced side effects include memory gaps or trouble focusing (sometimes referred as the “brain fog” connected with topiramate), as well as a changed sense taste for particular foods (carbonated drinks can taste “flat” or different on topiramate). Particularly early in treatment, when the body adapts to the stimulant and dopaminergic elements, irritability, worry, or restlessness might show themselves.

One should keep a close eye on cardiovascular-related side effects. Because phentermine and caffeine are sympathomimetic, Bella can cause a small rise in heart rate and blood pressure. Particularly if they are sensitive to stimulants, some patients may experience a racing heartbeat or heart palpitations. Regular blood pressure and pulse readings are advised throughout treatment; if sustained hypertension or tachycardic develops, the dose might need to be changed or Bella terminated.

Though some previous weight-loss medications (such as fenfluramine in the outdated “fenphen” combination) have worried over valvular heart disease, current data have not revealed Phentermine/topiramate’s important evidence of valve damage. Still, healthcare professionals usually get a baseline cardiac assessment and will reevaluate patients if they experience chest pain, breathlessness, or edema while on Bella.

Bella’s neuropsychiatric side effects also merit attention. Mood swings can happen; some people feel more nervous, while others may have better mood (bupropion is an antidepressant), but then a “crash” or irritability as the stimulant effects wear off. Rarely, the bupropion ingredient has been linked to suicidal thoughts or worsening depression—especially in younger patients.

Use of Bella Capsules in Pregnancy and Breastfeeding – What You Should Know

Bella Capsules are not safe to use during pregnancy. This is because several of the ingredients in the product, such as topiramate and phentermine, are linked with risks to the developing baby. Topiramate has been associated with birth defects like cleft lip or palate when used in early pregnancy, while phentermine may reduce blood flow to the uterus, potentially causing stress to the fetus. Weight-loss during pregnancy is also discouraged, as it can harm the baby’s development, even for women with obesity. Therefore, women of child-bearing potential must use reliable contraception while taking Bella. If a patient becomes pregnant while using Bella, it should be stopped immediately, and therapy should not be restarted until after delivery – if at all.

Breastfeeding Considerations

Breastfeeding while using Bella is also not recommended, because the ingredients can pass into breast milk and potentially affect the baby:

Bupropion passes into breast milk in small amounts, but some infants may be sensitive, potentially experiencing seizures or irritability. Alternatives like sertraline may be safer for breastfeeding mothers needing depression treatment.

Phentermine is not advised during breastfeeding because it could cause serious side effects in infants, even though it’s unclear how much passes into milk.

Experts recommend carefully weighing the benefits of breastfeeding against potential risks.

Naltrexone is also found in breast milk, but the effects on infants are not well understood. Still, it’s advisable to monitor infants for any adverse reactions.

Methylcobalamin (Vitamin B12), on the other hand, is considered safe and beneficial during breastfeeding.

Caffeine, found in some formulations, can build up in a baby’s system, leading to irritability or sleep disturbances, especially if consumed in large amounts.

Oxytocin naturally plays a role in breastfeeding and milk release, but while it’s excreted in milk, it’s not expected to harm infants.

Metformin, used for managing blood sugar, is passed into breast milk in tiny amounts that are unlikely to affect the baby. Studies suggest it’s probably safe, but mothers should be cautious and consult their doctor.

What’s the bottom line?

Pregnancy: Bella Capsules should never be used, and women must use contraception while on therapy.

Breastfeeding: Many ingredients can pass into breast milk, possibly harming the baby. Use of Bella is generally not recommended during breastfeeding, except for vitamin B12 and, in some cases, metformin under medical supervision.

Decisions about breastfeeding while on medication should always balance the health benefits for the mother with potential risks to the baby.

Always discuss your treatment and breastfeeding plans with your healthcare provider to ensure the safest outcomes for both you and your baby.

Bella Capsules should be stored at room temperature (around 20-25 °C or 68-77 °F), in a dry place away from excessive heat or light. They should be kept in their original packaging or a tightly sealed container to protect them from moisture.

As with all medications, Bella should be kept out of reach of children and pets – the ingredients can be harmful if accidentally ingested by others.

Do not use any capsules beyond their labeled expiration or beyond-use date. If a capsule is damaged or shows signs of degradation (e.g. an unusual odor or discoloration), consult the pharmacy about proper disposal and do not consume it.

Unused or expired Bella Capsules should be disposed of in accordance with pharmacy or FDA guidelines (for example, via a medication take-back program rather than simply thrown in the trash).

1. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
2. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801.
3. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57:1583-1588.
4. Institute for Clinical Systems Improvement (ICSI). Major depression in adults for mental health care. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2004 May. Available on the World Wide Web at www.guideline.gov
5. Care Management Institute, Kaiser Permanente. Adult primary care depression guidelines. Oakland (CA): Kaiser Permanente; 2004 Apr. Retrieved October 27, 2005. Available on the World Wide Web at www.guidelines.gov
6. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. Am J Psychiatry 2000;157(4 Suppl):1-45.
7. Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 2005;58:658-67.
8. Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
9. Topamax (topiramate) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2021 Jun.
10. Trokendi XR (topiramate extended-release capsules) package insert. Rockville, MD: Supernus Pharmaceuticals; 2020 Nov.
11. Qudexy XR (topiramate) package insert. Maple Grove, MN: Upsher-Smith Laboratories; 2021 Feb.
12. Silberstein SD, Holland S, Freitag F, et al. Evidence based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-1345.
13. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2018;59:1-18.
14. Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019 [Epub ahead of print]
15. McElroy SL. Pharmacologic treatments for binge-eating disorder. J Clin Psychiatry 2017;78:14-19.
16. Work Group on Alcohol Use Disorder, American Psychiatric Association. Practice guideline for the pharmacological treatment of patients with alcohol use disorder. American Psychiatric Association 2018. Available on the web at https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9781615371969 – LinkOpens in New Tab
17. Pringsheim T, Okun MS, Muller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019;92:896-906.
18. O’Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279:229-234.
19. Scanlon JEM, Chin KC, Morgan MEI, et al. Caffeine or theophylline for neonatal apnea? Arch Dis Child 1992;67:425-8.
20. Cabanac M, Pfaff DW, Ogawa S, et al. Neural oxytocinergic systems as genomic targets for hormones and as modulators of hormone-dependent behaviors. Results Probl Cell Differ 1999;26:91-105.
21. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43:270-277.
22. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995;18:779-84.
23. Hermann LS, Scherstein B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone, and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9.
24. Kosasa TS. Making a Case for Metformin. OB/GYN 2003;48:69-80.
25. Ibanez L, Ong K, Valls C, et al. Metformin treatment to prevent early puberty in girls with precocious puberty. J Clin Endocrinol Metab 2006;91:2888-91.
26. Ibanez L, Valls C, Ong K, et al. Metformin therapy during puberty delays menarche, prolongs puberal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 2006;0:2068-73.
27. Doggrell SA. Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Expert Opin Pharmacother 2002;3:1011-3.
28. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes
29. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(suppl1):S11-S63.
30. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(suppl1):S14-S80.
31. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
32. Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004; 20(4):565-72.
33. 31285
34. Wagstaff AJ, Figgit DP. Extended-release metformin hydrochloride. Single composition osmotic tablet formulation. Treat Endocrinol 2004;3:327-32.
35. Bryant SG, Guernsey BG, Ingrim NB. Review of bupropion. Clin Pharm 1983;2:525-37.
36. Adipex-P (phentermine hydrochloride tablets and capsules) package insert. Sellersville, PA: Teva Pharmaceuticals; 2013 Jan.
37. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318:604-610.
38. Filippi L, Fiorini P, Daniotti M. Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI). BMC Pediatrics 2012;12:144-155.
39. American College of Obstetrics and Gynecology (ACOG). ACOG Practice Bulletin Number 10: Clinical Management Guidelines for Obstetrician-Gynecologists. Induction of labor. Washington, DC: American College of Obstetricians and Gynecologists; November 1999.
40. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
41. Wellbutrin XL (bupropion) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2019 Nov.
42. Wellbutrin SR (bupropion) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2020 Oct.
43. Wellbutrin XL (bupropion) package insert. Bridgewater, NJ: Bausch Health US, LLC; 2019 Nov.
44. Wellbutrin (bupropion) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2020 Oct.
45. Zyban (bupropion sustained release tablets) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2021 Mar.
46. Aplenzin (bupropion extended-release tablet) package insert. Bridgewater, NJ: Sanofi-aventis, LLC.; 2020 May.
47. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American HeartAssociation Council on Cardiovascular Disease in the Young Congenital Heart Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407-23.
48. Forfivo XL (bupropion hydrochloride extended-release tablets) package insert. Buffalo, NY: IntelGenx Corp; 2019 Dec.
49. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23:21-31.
50. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:211-4.
51. US Food and Drug Administration (FDA). FDA Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. Retrieved Dec 22, 2016. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm532221.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery – LinkOpens in New Tab
52. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009:CD001055
53. Massachusetts General Hospital Center for Women’s Mental Health. National Pregnancy Registry for Psychiatric Medications. Available on the World Wide Web at: https://womensmentalhealth.org/research/pregnancyregistry/ – LinkOpens in New Tab
54. Haas JS, Kaplan CP, Barenboim D, et al. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control 2004;13:52-6.
55. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of a possible infant seizure. J Clin Psychiatry 2004;65:881-2.
56. Baab SW, Peindl KS, Piontek CM, et al. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry 2002;63:910-11.
57. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004;161:1066-78.
58. DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children’s health. Pediatrics. 2004;113:1007-1015.
59. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
60. Adipex-P (phentermine hydrochloride tablets and capsules) package insert. Sellersville, PA: Teva Pharmaceuticals; 2013 Jan.
61. Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
62. Phentermine hydrochloride package insert. Newtown, PA: KVK-Tech Inc; 2010 April.
63. Steiner E, Villen T, Hallberg M, et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 1984;27:123-4.
64. Kelly TE, Hackett PH. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol 2010;11:319-323.
65. Brackett CC. Sulfonamide allergy and cross-reactivity. Curr Allergy Asthma Rep 2007;7:41-48.
66. Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol 2012;69:527-529.
67. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. New Engl J Med 2003;349:1628-35.
68. Ben-Zeev B, Watemberg N, Augarten A, et al. Oligohydrosis and hyperthermia: a pilot study of a novel topiramate adverse effect. J Child Neurol 2003;18:254-7.
69. Yamamoto Y, Takahashi Y, Imai K. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia 2013;54:983-989.
70. The American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;00:1-21.
71. Food and Drug Administration MedWatch. Topamax (topiramate): label change – risk for development of cleft lip and/or cleft palate in newborns. Retrieved March 4, 2011. Available on the World Wide Web http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245777.htm – LinkOpens in New Tab
72. Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002;43:1157-60.
73. Naltrexone (naltrexone hydrochloride) package insert. Hazelwood, MO: Mallinckrodt, Inc. 2009 Feb.
74. Vivitrol (naltrexone extended release injectable suspension) package insert. Waltham, MA: Alkermes, Inc.; 2021 Mar.
75. Revia (naltrexone hydrochloride) package insert. Pomona, NY: Duramed Pharmaceuticals, Inc. 2013 Oct.
76. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
77. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr 2000;39:327-36.
78. Cafcit (caffeine citrate) package insert. Eatontown, NJ: West-Ward Pharmaceuticals; 2019 Dec.
79. Erenberg A, Leff RD, Haack DG, et al. Caffeine Citrate for the Treatment of Apnea of Prematurity: A Double-Blind, Placebo-Controlled Study. Pharmacotherapy 2000;20(6):644-652.
80. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965-971.
81. Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64:51-78.
82. Hadeed A, Siegel S. Newborn cardiac arrhythmias associated with maternal caffeine use during pregnancy. Clin Pediatr 1993;32:45-7.
83. Le Guennec JC, Billon B. Delay in caffeine elimination in breast-fed infants. Pediatrics 1987;79:264-8.
84. Berlin CM, Denson HM, Daniel CH, et al. Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. Pediatrics 1984;73:59-63.
85. Tyrala EE, Dodson WE. Caffeine secretion into breast milk. Arch Dis Child 1979;54:787-800.
86. Hill RM, Craig JP, Chaney MD, et al. Utilization of over-the-counter drugs during pregnancy. Clin Obstet Gynecol 1977;20:381-94.
87. Awake (caffeine) tablet package insert. Deerfield, IL: Walgreen Co. 05/214.
88. Mangesi L, Dowswell T. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2010;9:CD006946.
89. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 2008;31:2086-91.
90. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the ADA and EASD. Diabetes Care 2012. Epub ahead of print, doi: 10.2337/dc12-0413
91. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1432-1437.
92. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335(7618):497 Epub 2007 Aug 30
93. Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-9.
94. Glucophage®/Glucophage® XR (metformin) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2009 Jan.
95. Vanky E, Zahlsen K, Spigset O, et al. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005;83:1575-8.
96. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum
97. Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-dependent diabetics. Diabetologia 1979;16:421-425.
98. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin Number 60: Pregestational diabetes mellitus. Obstet Gynecol 2005;105:675-85.
99. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin Number 30: Gestational diabetes. Obstet Gynecol 2001;98:525-38.
100. Dhulkotia JS, Ola B, Fraser R, et al. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:457.
101. Balani J, Hyer SL, Rodin DA, et al. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med 2009;26:798-802.
102. Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. Diabetologia 2002;45:1509-14.
103. Gardiner SJ, Kirkpatrick CMJ, Begg EJ, et al. Transfer of metformin into human milk. Clin Pharmacol Ther 2003;73:71-7.
104. Briggs GG, Ambrose PJ, Nageotte MP, et al. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol 2005;105:1437-41.
105. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social development in breast- and formula- fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr 2006;148:628-32.
106. Everett J. Use of oral antidiabetic agents during breastfeeding. J Hum Lact 1997;13:319-21.
107. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
108. Spencer JP, Gonzalez LS, Barnhart DJ. Medications in the breast-feeding mother. Am Fam Physician; 64:119-26.
109. Food and Drug Administration Adverse Event Reporting System. Potential signals of serious risks/new safety information identified from the FDA adverse event reporting system (FAERS): July – September 2017. Available on the worldwide web at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm592379.htm – LinkOpens in New Tab
110. Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine 2014;81:15-21.
111. Spriet S, Banks TA. Drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Proc 2015;36:501-5.
112. Institute for Safe Medication Practices (ISMP). Acute Care ISMP Medication Safety Alert 2018;23:1-2.
113. Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
114. Phentermine hydrochloride package insert. Newtown, PA: KVK-Tech Inc; 2010 April.
115. Lomaira (phentermine hydrochloride) package insert. Newton, PA: KVK-Tech, Inc.; 2016 Sept.
116. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38:292-298.
117. Depakote (divalproex sodium tablets) package insert. North Chicago, IL: AbbVie Inc.; 2020 May.
118. Page RL, Bainbridge JL. Intractable Epistaxis Associated with Topiramate Administration. Ann Pharmacother. 2006; Accessed online on July 5, 2006. Published Online, 5 July 2006. Available on the World Wide Web at: www.theannals.com, DOI 10.1345/aph.1H078
119. Kossoff EH, Pyzik PL, Furth SL. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002;43:1168-1171.
120. Groeper K, McCann ME. Topiramate and metabolic acidosis: a case series and review of the literature. Paediatr Anaesth 2005;15:167-70.
121. Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;40:792-5.
122. Nawrot P, Jordan S, Eastwood J, et al: Effects of caffeine on human health. Food Addit Contam 2003;20:1-30.
123. Schmidt B, Roberts RS, Davis P, et al. Caffeine Therapy for Apnea of Prematurity. N Engl J Med 2006; 354:2112-2121.
124. lane AJ, Coombs RC, et al. Effect of caffeine on neonatal splanchnic blood flow. Arch Dis Child Fetal Neonatal Ed 1999;80:F128-F129.
125. Bhatt-Mehta V, Schumacher RE. Treatment of apnea of prematurity. Pediatr Drugs 2003;5:195-210.
126. Caffeine tablets alertness aid supplement (product label). Woonsocket RI, CVS; 2012.
127. Pollak C, Bright D. Caffeine consumption and weekly sleep patterns in US seventh-, eighth-, and ninth-graders. Pediatrics 2003;111:42-46.
128. Davis R, Osorio I: Childhood caffeine tic syndrome. Pediatrics 1998;101:E4.
129. Prolab Caffeine supplement product label. Chatsworth, CA Prolab Nutrition Inc; 2012.
130. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99.
131. Pitocin (oxytocin) package insert. Rochester, MI: JHP Pharmaceuticals, LLC; 2014 Sept.
132. Curless RV, Beaumont DM, Sinar EJ, et al. Subarachnoid hemorrhage mimicking acute water intoxication during labour augmented by oxytocin infusion. Br J Clin Pract 1990;44(12):637-638.